In a nutshell
This study reviewed the long-term effects of levodopa/carbidopa intestinal gel (LCIG; Duodopa®) in patients with Parkinson´s disease (PD) and wearing-off symptoms. This study concluded that LCIG reduced off-time and improved off-symptoms in the long-term in these patients.
Some background
PD is a chronic disorder that affects brain cells. Over time, these cells stop controlling body functions causing symptoms such as tremors. The standard treatment is oral levodopa. However, its long-term use causes wearing-off symptoms. Off symptoms consist of PD symptoms coming back before the next levodopa dose, sometimes worse.
LCIG is a gel of continuous delivery into the intestine through a tube. This method of delivery helps levodopa in the bloodstream to last longer, reducing off symptoms. Prior studies suggested that LCIG reduces off-time, improving daily activities and the quality of life of patients. However, it is still not clear how long patients might benefit from LCIG.
Methods & findings
This study reviewed 27 other studies with information about patients with PD and off-symptoms.
An improvement in off-symptoms was observed shortly after LCIG treatment and lasted until the follow-up period. Off-time was reduced by 38% to 84% from the start to the end of treatment. This reduction led to an improvement in quality of life.
The average reduction was between 47 and 82% at 3 to 6 months of follow-up and up to 83% at 3 to 5 years. Most patients reported improvement in daily activities and movement complications. The most frequent side effects were associated with the procedure or the device. These included infection of the site where the tube was implanted, belly pain, or movement of the tube.
The bottom line
This study concluded that LCIG reduced off-time and improved off-symptoms in patients with advanced PD in the long-term.
The fine print
This study was funded by AbbVie, the LCIG manufacturer.
Published By :
Advances in therapy
Date :
May 21, 2021
